Trial site
A-Shine s.r.o.
Plzen 3, 301 00, CzechiaEU-13 widening countryNot linked to an institution yet
- 19running trials
- 17closed trials
The trials here
What the 36 trials at this site are about, from their registry records.
- Phase
- Phase 325 trials
- Phase 210 trials
- Phase 2/31 trial
- Status
- Completed17 trials
- Recruiting12 trials
- Active, not recruiting5 trials
- Not yet recruiting2 trials
- Lead sponsor
- AbbVie3 trials
- Bristol-Myers Squibb3 trials
- Intra-Cellular Therapies, Inc.3 trials
- Neurocrine Biosciences3 trials
- Boehringer Ingelheim International GmbH2 trials
- and 19 more
Running trials
Active, not recruiting
Evenamide in patients with treatment-resistant schizophrenia not responding to antipsychotics
2024-519836-18-00· Phase 3· Newron Pharmaceuticals S.p.A.· Source
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397· Phase 3· Cybin IRL Limited· Source
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· Phase 3· Bristol-Myers Squibb· Source
Enrolling by invitation
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
NCT07161700· Phase 2· Seaport Therapeutics· Source
Enrolling by invitation
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
NCT06605105· Phase 3· Cybin IRL Limited· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
NCT07065240· Phase 2· Seaport Therapeutics· Source
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· Phase 3· Neurocrine Biosciences· Source
Recruiting
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044· Phase 3· Vanda Pharmaceuticals· Source
Active, not recruiting
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595· Phase 3· Definium Therapeutics US, Inc.· Source
Recruiting
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624· Phase 3· Neurocrine Biosciences· Source
Recruiting
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
NCT06701903· Phase 2· Intra-Cellular Therapies, Inc.· Source
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source
Recruiting
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383· Phase 2· Intra-Cellular Therapies, Inc.· Source
Recruiting
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression
2023-505268-12-00· Phase 3· Compass Pathfinder Limited· Source
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Active, not recruiting
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· Phase 3· AriBio Co., Ltd.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Active, not recruiting
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06806293· Phase 3· AbbVie· Source
Completed
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
2024-511057-22-00· Phase 3· Janssen Cilag International· Source
Completed
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder
NCT06029439· Phase 3· Neumora Therapeutics Inc.· Source
Completed
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine
2023-507942-10-00· Phase 2· Boehringer Ingelheim International GmbH· Source
Completed
Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder
NCT06058039· Phase 3· Neumora Therapeutics, Inc.· Source
Completed
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· Phase 2· Prinnovation GmbH· Source
Completed
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
NCT05748483· Phase 3· AbbVie· Source
Completed
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
2022-502233-25-00· Phase 3· Neurocrine Biosciences Inc.· Source
Completed
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.
2023-508163-74-00· Phase 3· Janssen Cilag International· Source
Completed
A Trial of GH001 in Patients With Treatment-resistant Depression
NCT05800860· Phase 2· GH Research Ireland Limited· Source
Completed
Protocol Lay Person Short Title: A Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder.
2022-500538-27-00· Phase 2/3· Otsuka Pharmaceutical Development And Commercialization Inc.· Source
Completed
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT05686239· Phase 2· Recognify Life Sciences· Source
Completed
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study
2024-511560-93-00· Phase 3· Boehringer Ingelheim International GmbH· Source
Completed
A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation
NCT05318976· Phase 2· Inmune Bio, Inc.· Source
Completed
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157· Phase 3· Neurocrine Biosciences· Source
Completed
A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
NCT04686136· Phase 3· AbbVie· Source
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
NCT04437511· Phase 3· Eli Lilly and Company· Source
Report an error